Basal cell carcinoma of skin of unspecified parts of face
ICD-10 C44.310 is a billable code used to indicate a diagnosis of basal cell carcinoma of skin of unspecified parts of face.
Basal cell carcinoma (BCC) is the most common form of skin cancer, primarily arising from the basal cells in the epidermis. This malignancy is characterized by slow growth and a low propensity for metastasis, making it less aggressive than other skin cancers. BCC typically presents as a pearly or waxy bump, a flat, flesh-colored lesion, or a scar-like area on the skin. The face is a common site for BCC due to sun exposure, which is a significant risk factor. Ultraviolet (UV) radiation from the sun damages the DNA in skin cells, leading to mutations that can result in cancer. Surgical excision is the primary treatment, with the goal of achieving clear surgical margins to minimize recurrence. Reconstruction may be necessary depending on the size and location of the excised lesion, particularly on the face, where cosmetic outcomes are crucial. Accurate coding of BCC is essential for appropriate treatment planning and reimbursement, and it requires careful documentation of the lesion's characteristics and treatment approach.
Detailed descriptions of the lesion, including size, location, and histological findings.
Diagnosis and treatment of BCC, Mohs micrographic surgery, and post-operative care.
Ensure accurate documentation of margins and any reconstructive procedures performed.
Comprehensive treatment plans, including chemotherapy or radiation if applicable.
Management of advanced BCC cases or those requiring systemic therapy.
Document any multidisciplinary approaches and follow-up care.
Used when excising a BCC from the face.
Document size, location, and margins of the excised lesion.
Dermatologists should ensure detailed operative notes.
The primary treatment for basal cell carcinoma is surgical excision, often using Mohs micrographic surgery for facial lesions to ensure complete removal while preserving healthy tissue.
